In this May 4, 2020 photo provided by the University of Maryland School of Medicine, the first patient enrolled in Pfizer’s COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection.
University of Maryland School of Medicine | AP
Pfizer could have results from its late-stage coronavirus vaccine trial as early as October, CEO Albert Bourla said Thursday.
The pharmaceutical company has already enrolled 23,000 volunteers in the phase three trial that began in late July, Bourla said during a Q&A with the International Federation of Pharmaceutical Manufacturers & Associations, a trade group. It hopes to enroll at least…